218 related articles for article (PubMed ID: 18826559)
21. Pathophysiological concepts of functional dyspepsia and irritable bowel syndrome future pharmacotherapy.
Dobrek Ł; Thor PJ
Acta Pol Pharm; 2009; 66(5):447-60. PubMed ID: 19894640
[TBL] [Abstract][Full Text] [Related]
22. Effects of antidepressants in patients with irritable bowel syndrome and comorbid depression.
Friedrich M; Grady SE; Wall GC
Clin Ther; 2010 Jul; 32(7):1221-33. PubMed ID: 20678672
[TBL] [Abstract][Full Text] [Related]
23. FDA and EMA end points: which outcome end points should we use in clinical trials in patients with irritable bowel syndrome?
Corsetti M; Tack J
Neurogastroenterol Motil; 2013 Jun; 25(6):453-7. PubMed ID: 23672677
[TBL] [Abstract][Full Text] [Related]
24. Investigational agents for the irritable bowel syndrome.
Ghaith O; El-Halabi M; Hashash JG; Sharara AI
Expert Opin Investig Drugs; 2010 Oct; 19(10):1161-78. PubMed ID: 20836617
[TBL] [Abstract][Full Text] [Related]
25. [Role of serotonin in the pathophysiology of the irritable bowel syndrome].
Moskwa A; Boznańska P
Wiad Lek; 2007; 60(7-8):371-6. PubMed ID: 18175558
[TBL] [Abstract][Full Text] [Related]
26. [Pharmacoeconomics and outcome research on Irritable Bowel Syndrome review of findings using Tegaserod].
Ariza JG; Martínez JA
Rev Gastroenterol Peru; 2006; 26(1):77-9. PubMed ID: 16622489
[TBL] [Abstract][Full Text] [Related]
27. Atypical antipsychotics as a possible treatment option for irritable bowel syndrome.
Pae CU; Lee SJ; Han C; Patkar AA; Masand PS
Expert Opin Investig Drugs; 2013 May; 22(5):565-72. PubMed ID: 23506326
[TBL] [Abstract][Full Text] [Related]
28. End points in irritable bowel syndrome.
Mangel AW; Fehnel SE
Expert Rev Gastroenterol Hepatol; 2011 Jun; 5(3):293-5. PubMed ID: 21651345
[No Abstract] [Full Text] [Related]
29. Primary endpoints for irritable bowel syndrome trials: a review of performance of endpoints.
Camilleri M; Mangel AW; Fehnel SE; Drossman DA; Mayer EA; Talley NJ
Clin Gastroenterol Hepatol; 2007 May; 5(5):534-40. PubMed ID: 17428741
[TBL] [Abstract][Full Text] [Related]
30. Review article: probiotics for the treatment of irritable bowel syndrome--focus on lactic acid bacteria.
Clarke G; Cryan JF; Dinan TG; Quigley EM
Aliment Pharmacol Ther; 2012 Feb; 35(4):403-13. PubMed ID: 22225517
[TBL] [Abstract][Full Text] [Related]
31. Emerging drug for diarrhea predominant irritable bowel syndrome.
Deiana S; Gabbani T; Bagnoli S; Annese V
Expert Opin Emerg Drugs; 2015 Jun; 20(2):247-61. PubMed ID: 25732091
[TBL] [Abstract][Full Text] [Related]
32. Postinfectious irritable bowel syndrome.
Barbara G; Cremon C; Pallotti F; De Giorgio R; Stanghellini V; Corinaldesi R
J Pediatr Gastroenterol Nutr; 2009 Apr; 48 Suppl 2():S95-7. PubMed ID: 19300138
[TBL] [Abstract][Full Text] [Related]
33. Measuring successful treatment of irritable bowel syndrome: is "satisfactory relief " enough?
Schoenfeld P; Talley NJ
Am J Gastroenterol; 2006 May; 101(5):1066-8. PubMed ID: 16696786
[TBL] [Abstract][Full Text] [Related]
34. The role of the endocannabinoid system in the pathophysiology and treatment of irritable bowel syndrome.
Storr MA; Yüce B; Andrews CN; Sharkey KA
Neurogastroenterol Motil; 2008 Aug; 20(8):857-68. PubMed ID: 18710476
[TBL] [Abstract][Full Text] [Related]
35. [Treatment for irritable bowel syndrome--psychotropic drugs, antidepressants and so on].
Sato M; Murakami M
Nihon Rinsho; 2006 Aug; 64(8):1495-500. PubMed ID: 16898620
[TBL] [Abstract][Full Text] [Related]
36. [Efficacy of alverina citrate and simethicone combination in abdominal pain and discomfort of irritable bowel syndrome].
Wittmann T; Paradovsky L; Ducrotte P; Bueno L; Andro-Delestrain MC
Eksp Klin Gastroenterol; 2011; (3):60-7. PubMed ID: 21698811
[TBL] [Abstract][Full Text] [Related]
37. Lower gastrointestinal disorders in patients with irritable bowel syndrome.
Jurcić D; Bilić A; Schwarz D; Luetic K; Marusić M; Vcev A; Gabrić M; Spoljarić L
Coll Antropol; 2008 Sep; 32(3):755-9. PubMed ID: 18982748
[TBL] [Abstract][Full Text] [Related]
38. Is there a role for probiotics in irritable bowel syndrome?
Camilleri M
Dig Liver Dis; 2006 Dec; 38 Suppl 2():S266-9. PubMed ID: 17259088
[TBL] [Abstract][Full Text] [Related]
39. Irritable bowel syndrome: new findings in pathophysiological and therapeutic field.
Catanzaro R; Occhipinti S; Calabrese F; Anzalone MG; Milazzo M; Italia A; Marotta F
Minerva Gastroenterol Dietol; 2014 Jun; 60(2):151-63. PubMed ID: 24780949
[TBL] [Abstract][Full Text] [Related]
40. Evolving concepts of the pathogenesis of irritable bowel syndrome: to treat the brain or the gut?
Camilleri M
J Pediatr Gastroenterol Nutr; 2009 Apr; 48 Suppl 2():S46-8. PubMed ID: 19300123
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
